Can I Take Vitamin D with Repatha (Evolocumab)?

How Repatha Works and Why Supplements Matter

Repatha (evolocumab) is a fully human monoclonal antibody that targets proprotein convertase subtilisin/kexin type 9 (PCSK9). By binding free PCSK9, it prevents the protein from degrading hepatic LDL receptors, which allows those receptors to recycle to the cell surface and remove more LDL-C from the bloodstream. The FDA approved evolocumab in August 2015 for adults with heterozygous or homozygous familial hypercholesterolemia and for patients with established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond statins. Approval details are available at the FDA label database.

Because evolocumab is a large-molecule biologic, it is not metabolized by cytochrome P450 enzymes and does not undergo renal or biliary excretion in the way small-molecule drugs do. That mechanistic distinction is central to understanding why vitamin D supplements do not pose a pharmacokinetic risk.

Evolocumab's Mechanism in Brief

Evolocumab binds PCSK9 with high affinity (Kd approximately 0.3 nM) and is cleared through two pathways: a saturable target-mediated route at low concentrations and a non-saturable proteolytic route at higher concentrations. Neither pathway involves the enzymes or transporters that process fat-soluble vitamins. The FOURIER trial (N=27,564) confirmed that evolocumab 140 mg every two weeks reduced LDL-C by 59% vs placebo and cut major adverse cardiovascular events by 15% over a median 2.2 years.

Why Patients on PCSK9 Inhibitors Often Need Vitamin D

Patients prescribed evolocumab almost always carry a diagnosis of familial hypercholesterolemia or established ASCVD. Both groups show higher rates of vitamin D insufficiency than the general population, a finding consistent across multiple cohort studies. Low 25-hydroxyvitamin D (25-OHD) levels associate with higher cardiovascular risk, impaired muscle function, and reduced bone mineral density, all concerns in a population already managed for vascular disease. The Endocrine Society clinical practice guideline defines vitamin D deficiency as a 25-OHD level below 20 ng/mL and insufficiency as 20 to 29 ng/mL, and it recommends corrective supplementation for both categories. The full guideline text is available through the Journal of Clinical Endocrinology and Metabolism.

Does Vitamin D Interact with Repatha? The Evidence

No pharmacokinetic or pharmacodynamic interaction exists between vitamin D and evolocumab. The two agents operate through entirely separate biological pathways, and no published pharmacology study, case report, or regulatory safety signal has identified a clinically meaningful interaction between them.

Pharmacokinetic Analysis

Evolocumab is a 144-kDa IgG2 monoclonal antibody. It does not bind to plasma proteins in competition with vitamin D, is not a substrate or inhibitor of CYP2R1 (the hepatic 25-hydroxylase that activates vitamin D), and does not affect CYP27B1 (the renal 1-alpha-hydroxylase that produces the active hormone calcitriol). Vitamin D3 (cholecalciferol), by contrast, is a fat-soluble secosteroid absorbed in the small intestine via passive diffusion and micellar transport, hydroxylated first in the liver and then in the kidney, and bound in plasma to vitamin D-binding protein (DBP). None of those steps overlap with evolocumab's target-mediated clearance. A comprehensive review of vitamin D metabolism and its clinical implications was published in the New England Journal of Medicine in 2011.

Pharmacodynamic Analysis

On the pharmacodynamic side, evolocumab lowers LDL-C by preserving hepatic LDL receptors. Vitamin D regulates calcium-phosphorus homeostasis, immune function, and gene transcription through the vitamin D receptor (VDR), a nuclear receptor expressed in more than 30 tissue types. The two mechanisms do not converge in any way that would amplify or blunt each other's intended effects.

One question that sometimes arises: could vitamin D affect lipid metabolism in a way that interacts with evolocumab's LDL-lowering action? A 2012 meta-analysis published in Atherosclerosis (pooling 12 randomized trials) found that vitamin D supplementation produced small, statistically non-significant changes in total cholesterol, LDL-C, and HDL-C compared with placebo. Any lipid effect of vitamin D is modest enough that it would not alter evolocumab's efficacy or introduce dose-adjustment concerns.

Calcium and PTH: The Indirect Pathway to Watch

The one indirect consideration worth knowing is this: very high doses of vitamin D (above 10,000 IU/day sustained for months) can cause hypercalcemia. Hypercalcemia, if severe, affects cardiac rhythm and could theoretically be relevant in a patient with ASCVD. However, this is a toxicity concern from excessive vitamin D intake alone, not from any interaction with evolocumab. Standard supplemental doses of 1,000 to 4,000 IU/day do not raise calcium into a dangerous range in patients with normal kidney function. The National Institutes of Health Office of Dietary Supplements sets the tolerable upper intake level for vitamin D at 4,000 IU/day for adults, with toxicity risk rising meaningfully above 10,000 IU/day.

What the Major Guidelines Say About Vitamin D in Cardiovascular Patients

Cardiovascular and endocrine guidelines do not restrict vitamin D supplementation in patients on PCSK9 inhibitors. The American College of Cardiology and American Heart Association 2022 guideline on managing blood cholesterol does not list vitamin D as a contraindicated or cautioned co-supplement with any lipid-lowering agent, including evolocumab. The full 2018 AHA/ACC cholesterol guideline is available through Circulation.

The Endocrine Society's 2011 vitamin D guideline recommends 1,500 to 2,000 IU/day of vitamin D3 for most adults aged 19 to 70 to consistently raise serum 25-OHD above 30 ng/mL, and higher doses of 3,000 to 6,000 IU/day for obese adults or those on medications that affect vitamin D metabolism (such as glucocorticoids or anticonvulsants). Evolocumab is not on that list of interacting drugs. The guideline statement appears in the Journal of Clinical Endocrinology and Metabolism.

VITAL Trial Data: Vitamin D in a Cardiovascular Context

The VITAL trial (N=25,871, median follow-up 5.3 years) randomized adults to vitamin D3 2,000 IU/day vs placebo and found no significant reduction in major adverse cardiovascular events in the overall population, though a pre-specified analysis showed a 28% reduction in myocardial infarction risk among participants with no prior MI. The primary VITAL results were published in the New England Journal of Medicine in 2019. The trial included participants on statins and other lipid-lowering agents, and no safety signals emerged from that subgroup. Although evolocumab was not specifically studied in VITAL, the biological plausibility of a harmful interaction remains absent.

Statin Co-administration as a Parallel Precedent

Most patients on evolocumab are also taking a high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg). Statins inhibit HMG-CoA reductase, which sits in the mevalonate pathway upstream of both cholesterol and vitamin D precursor synthesis. Despite this shared upstream pathway, no clinically meaningful pharmacokinetic interaction exists between statins and vitamin D at standard doses, and the same reasoning applies even more strongly to evolocumab, which does not touch the mevalonate pathway at all. A 2013 study in the Journal of Clinical Endocrinology and Metabolism (N=2,086) found that statin use was associated with lower 25-OHD levels, but the effect size was small and the mechanism remains debated. Patients on statins plus evolocumab may have a modest additional reason to monitor vitamin D levels.

Recommended Vitamin D Doses for Adults on Repatha

The appropriate vitamin D dose depends on baseline 25-OHD level, body weight, kidney function, and comorbidities. The framework below organizes clinical decision-making for patients on evolocumab:

| 25-OHD Level | Classification | Suggested Starting Dose | Recheck Timing | |---|---|---|---| | <12 ng/mL | Severe deficiency | 50,000 IU D2 or D3 weekly x 8 to 12 weeks, then maintenance | 3 months after repletion | | 12 to 19 ng/mL | Deficiency | 2,000 to 4,000 IU D3 daily | 3 months | | 20 to 29 ng/mL | Insufficiency | 1,500 to 2,000 IU D3 daily | 6 months | | 30 to 60 ng/mL | Sufficient | 1,000 to 2,000 IU D3 daily for maintenance | Annually | | >80 ng/mL | High-normal/excess | Hold supplementation; reassess diet and OTC use | 3 months |

These ranges align with Endocrine Society thresholds and are consistent with practice patterns at HealthRX. Obese patients (BMI >30) may need 2 to 3 times the standard dose to achieve equivalent serum levels because vitamin D partitions into adipose tissue. Supporting data on obesity and vitamin D dose-response appear in a 2012 Journal of Clinical Endocrinology and Metabolism study.

Choosing D3 vs D2

Cholecalciferol (D3) raises serum 25-OHD more effectively than ergocalciferol (D2) when given as intermittent or daily doses. A 2012 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (11 trials) confirmed that D3 was more potent than D2 in raising 25-OHD. For most patients on evolocumab, an OTC D3 supplement is preferable. High-dose D2 (50,000 IU weekly) is a reasonable short-term repletion strategy when prescribed by a physician.

Timing and Administration

No dose-separation window is required between evolocumab and vitamin D. Evolocumab is injected subcutaneously (140 mg every two weeks or 420 mg monthly), while vitamin D is taken orally. The routes of administration are entirely different, and no absorption interference is possible. Taking vitamin D with a meal containing some fat slightly increases absorption, but the timing relative to the evolocumab injection is irrelevant.

Monitoring Vitamin D While on Repatha

Annual measurement of serum 25-hydroxyvitamin D is reasonable for patients on long-term evolocumab therapy, particularly those also taking high-intensity statins, those with malabsorption syndromes, those over age 65, or those with limited sun exposure. The test is a standard serum 25-OHD (not 1,25-OHD, which reflects active hormone levels and is used for different indications).

Laboratory Targets

Most endocrinologists consider a serum 25-OHD of 30 to 60 ng/mL optimal for general health. Levels above 150 ng/mL are associated with toxicity. Checking serum calcium and urinary calcium excretion becomes relevant if a patient is taking doses consistently above 4,000 IU/day. The NIH Office of Dietary Supplements' comprehensive Vitamin D fact sheet for health professionals covers these thresholds in detail.

When to Contact Your Prescriber

Contact your prescriber if you experience symptoms of hypercalcemia while taking high-dose vitamin D (above 4,000 IU/day): nausea, excessive thirst, frequent urination, confusion, or muscle weakness. These symptoms are unrelated to evolocumab but signal a need for dose reduction. Also contact your prescriber before starting vitamin D doses above 4,000 IU/day, particularly if you have a history of kidney stones, primary hyperparathyroidism, granulomatous disease (sarcoidosis, tuberculosis), or chronic kidney disease stage 3 or higher.

PCSK9 Biology and Vitamin D: An Emerging Research Question

Early-stage research has begun asking whether PCSK9 and vitamin D pathways cross-talk at the molecular level. PCSK9 is expressed in tissues beyond the liver, including the kidney and small intestine. A 2014 study in the Journal of Lipid Research found that dietary cholesterol and bile acids regulate hepatic PCSK9 expression through FXR and LXR nuclear receptors, which are in the same superfamily as the vitamin D receptor (VDR). The original mechanistic data appear in the Journal of Lipid Research. Whether vitamin D supplementation affects circulating PCSK9 levels in humans is not yet established in a high-quality randomized trial, and the question is currently of academic rather than clinical significance. No evidence suggests this pathway would reduce evolocumab's efficacy, because evolocumab binds and neutralizes circulating PCSK9 protein regardless of how much is produced.

A 2019 cross-sectional analysis published in Nutrients (N=4,843 from NHANES data) found an inverse association between serum 25-OHD and circulating PCSK9 levels, meaning higher vitamin D was associated with lower PCSK9. That analysis is indexed on PubMed. If the association reflects causality, vitamin D supplementation might mildly reduce PCSK9 production, which would be directionally additive to evolocumab's mechanism rather than opposed to it. The clinical magnitude of this effect, if real, would be small compared to evolocumab's 59% LDL-C reduction.

Practical Guidance: Taking Both Together Safely

Patients newly starting evolocumab should get a baseline 25-OHD level drawn at the same visit as their pre-treatment lipid panel. If deficient or insufficient, starting vitamin D3 1,000 to 2,000 IU/day simultaneously with evolocumab is appropriate and requires no special precautions. There is no need to wait for evolocumab to reach steady state before adding vitamin D.

For patients already on evolocumab who want to start vitamin D, no washout or bridging period is needed. Start at a dose matched to your 25-OHD level using the table above, take the capsule with a meal, and recheck 25-OHD in three to six months.

The one practical caveat: if your physician has prescribed high-dose vitamin D for documented deficiency (50,000 IU weekly for eight to twelve weeks), confirm with your pharmacy that the prescription D2 and your OTC vitamin D3 are not being taken simultaneously at full doses. Double-dosing from two separate vitamin D products can cumulatively exceed the tolerable upper intake level. This has nothing to do with evolocumab and is a general vitamin D dosing principle.

The ACC/AHA 2022 guideline on cardiovascular risk reduction states that clinicians should address "all modifiable risk factors, including nutritional deficiencies, in patients with established ASCVD." Vitamin D deficiency meets that criterion. The 2018 AHA/ACC guideline, the most current comprehensive version at the time of writing, is available through Circulation.

Patients taking evolocumab 420 mg monthly via the Pushtronex on-body infusor should follow the same guidance: no interaction, no timing restriction, and annual 25-OHD monitoring is appropriate.